Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $194 | $210 | $190 | $186 |
| - Cash | $11 | $13 | $8 | $12 |
| + Debt | $31 | $26 | $28 | $31 |
| Enterprise Value | $214 | $223 | $210 | $205 |
| Revenue | $52 | $47 | $52 | $53 |
| % Growth | 10.8% | -10% | -2% | – |
| Gross Profit | $39 | $35 | $36 | $37 |
| % Margin | 75.2% | 74.2% | 70.1% | 70% |
| EBITDA | $21 | $20 | $15 | $17 |
| % Margin | 40.1% | 41.8% | 29.3% | 32.5% |
| Net Income | $12 | $15 | $7 | $24 |
| % Margin | 23.1% | 31.8% | 13.4% | 45.4% |
| EPS Diluted | 5.87 | 7.58 | 3.27 | 10.65 |
| % Growth | -22.6% | 131.8% | -69.3% | – |
| Operating Cash Flow | $18 | $14 | $14 | $15 |
| Capital Expenditures | -$4 | -$3 | -$3 | -$3 |
| Free Cash Flow | $14 | $12 | $12 | $12 |